Corcept Therapeutics Incorporated (0I3Q.L)
- GuruFocus.com
Corcept Therapeutics Inc (CORT) Outperforms Analyst Estimates in Q1 2024
Revenue and Earnings Surge Amid Expanding Market Presence
- GlobeNewswire
Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
MENLO PARK, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter ended March 31, 2024. Financial Results Revenue of $146.8 million, a 39 percent increase over the same period in 2023Increase in 2024 revenue
- GlobeNewswire
Corcept Completes Enrollment in Phase 4 CATALYST Trial
MENLO PARK, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced completion of enrollment in CATALYST, a Phase 4 trial examining the prevalence of hypercortisolism (Cushing’s syndrome) in patients with difficult-to-control type 2 di
